瑞德西韦与肺部药物的潜在相互作用：从新冠肺炎角度看
Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective.
作者信息
Gandhi Zainab, Mansuri Zeeshan, Bansod Snehal
机构信息
Department of Infectious Diseases, University of California, San Francisco, CA USA.
Department of Psychiatry, Texas Tech University Health Science Center at Odessa/Permian Basin, Odessa, TX USA.
出版信息
SN Compr Clin Med. 2020;2(10):1707-1708. doi: 10.1007/s42399-020-00462-2. Epub 2020 Aug 21.
Abstract
In this letter, we discuss the potential interactions of remdesivir, the newly approved Covid-19 drug with pulmonary medications. These interactions have been summarized keeping the busy clinician in mind. While remdesivir has proven to be a safe medication generally, we here have enlisted the potential interactions of remdesivir that a clinician needs to be mindful of while prescribing the medication.
摘要
在这封信中，我们讨论了新获批的治疗新冠病毒病药物瑞德西韦与肺部用药之间可能存在的相互作用。总结这些相互作用时，我们考虑到了忙碌的临床医生的需求。虽然瑞德西韦总体上已被证明是一种安全的药物，但我们在此列出了临床医生在开具该药物处方时需要留意的瑞德西韦的潜在相互作用。
相似文献
1
Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective.瑞德西韦与肺部药物的潜在相互作用：从新冠肺炎角度看
SN Compr Clin Med. 2020;2(10):1707-1708. doi: 10.1007/s42399-020-00462-2. Epub 2020 Aug 21.
2
Remdesivir-COVID-19: drug interactions in dentistry.瑞德西韦-COVID-19：牙科中的药物相互作用。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9739-9743. doi: 10.26355/eurrev_202009_23065.
3
Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19.中度至重度新型冠状病毒肺炎紧急使用授权药物的药理学与不良事件
Pharmaceuticals (Basel). 2021 Sep 23;14(10):955. doi: 10.3390/ph14100955.
4
Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness.新型冠状病毒肺炎（COVID-19）的肝脏表现及瑞德西韦对COVID-19患者肝功能的影响。
Proc (Bayl Univ Med Cent). 2021 Mar 8;34(4):473-477. doi: 10.1080/08998280.2021.1885289.
5
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.瑞德西韦治疗 COVID-19：肺部和静脉联合给药可能提供额外益处。
AAPS J. 2020 May 26;22(4):77. doi: 10.1208/s12248-020-00459-8.
6
Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice.瑞德西韦对小鼠肺纤维化的保护作用
Front Pharmacol. 2021 Aug 26;12:692346. doi: 10.3389/fphar.2021.692346. eCollection 2021.
7
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.瑞德西韦的吸收、分布、代谢、排泄及药代动力学特性：其药物相互作用潜力
Pharmaceuticals (Basel). 2021 Jul 8;14(7):655. doi: 10.3390/ph14070655.
8
Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic.制定伦理框架以在 COVID-19 大流行期间分配瑞德西韦。
Mayo Clin Proc. 2020 Sep;95(9):1946-1954. doi: 10.1016/j.mayocp.2020.06.016. Epub 2020 Jun 20.
9
Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis.瑞德西韦对COVID-19的死亡率益处：一项系统评价和荟萃分析。
Front Med (Lausanne). 2021 Jan 27;7:606429. doi: 10.3389/fmed.2020.606429. eCollection 2020.
10
Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19.用于靶向肺部递送的脂质体瑞德西韦吸入溶液作为治疗新冠肺炎的一种新方法。
Asian J Pharm Sci. 2021 Nov;16(6):772-783. doi: 10.1016/j.ajps.2021.09.002. Epub 2021 Oct 21.
引用本文的文献
1
Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection.影响用于新型冠状病毒感染的常见抗病毒药物治疗活性的羧酸酯酶因素。
Pharmaceutics. 2025 Jun 26;17(7):832. doi: 10.3390/pharmaceutics17070832.
2
Comparative Epidemiological and Clinical Outcomes on COVID-19 and Seasonal Influenza Hospitalized Patients during 2023.2023年新冠病毒病（COVID-19）与季节性流感住院患者的比较流行病学和临床结局
Infect Dis Rep. 2024 Aug 23;16(5):783-793. doi: 10.3390/idr16050060.
3
Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution.在新冠病毒感染中开具选择性5-羟色胺再摄取抑制剂需谨慎。
Front Psychiatry. 2022 Oct 19;13:1052710. doi: 10.3389/fpsyt.2022.1052710. eCollection 2022.
4
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.COVID-19 口服药物莫努匹韦是 CES2 的底物：潜在的药物-药物相互作用和 CES2 遗传多态性的体外影响。
Drug Metab Dispos. 2022 Sep;50(9):1151-1160. doi: 10.1124/dmd.122.000918. Epub 2022 Jul 5.
5
A phase I trial of cyclosporine for hospitalized patients with COVID-19.一项环孢素治疗 COVID-19 住院患者的 I 期临床试验。
JCI Insight. 2022 Jun 8;7(11):e155682. doi: 10.1172/jci.insight.155682.
6
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.抗抑郁药氟西汀和氟伏沙明在治疗新型冠状病毒肺炎中的潜在作用
Int J Mol Sci. 2022 Mar 30;23(7):3812. doi: 10.3390/ijms23073812.
7
Characterization of Clofazimine as a Potential Substrate of Drug Transporter.鉴定氯法齐明作为药物转运体的潜在底物。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0215821. doi: 10.1128/aac.02158-21. Epub 2022 Mar 7.
8
Old Problem, New Concerns: Hypercortisolemia in the Time of COVID-19.旧问题，新担忧：COVID-19 时期的皮质醇增多症。
Front Endocrinol (Lausanne). 2021 Oct 5;12:711612. doi: 10.3389/fendo.2021.711612. eCollection 2021.
9
Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.COVID-19期间泌尿外科药物治疗及疫苗接种的药物治疗方法：一项叙述性综述
Ther Adv Urol. 2021 Sep 28;13:17562872211046794. doi: 10.1177/17562872211046794. eCollection 2021 Jan-Dec.
10
Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?将瑞德西韦与P-糖蛋白和CYP3A4联合抑制剂联合使用是否安全？
Eur J Hosp Pharm. 2021 Mar;28(2):e6. doi: 10.1136/ejhpharm-2021-002680. Epub 2021 Jan 20.
本文引用的文献
1
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.瑞德西韦治疗新型冠状病毒肺炎：药理学、临床前及临床研究的批判性综述
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):641-648. doi: 10.1016/j.dsx.2020.05.018. Epub 2020 May 12.
2
A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.一种用于新冠病毒大流行管理的精准医学方法。
Curr Treat Options Allergy. 2020;7(3):422-440. doi: 10.1007/s40521-020-00258-8. Epub 2020 May 8.
3
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.2019年冠状病毒病的治疗：早期及新出现的治疗选择综述
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. eCollection 2020 Apr.
4
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir.瑞德西韦抑制埃博拉病毒 RNA 依赖的 RNA 聚合酶的机制。
Viruses. 2019 Apr 4;11(4):326. doi: 10.3390/v11040326.
5
Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.个性化医疗的临床应用：一种新范式与挑战。
Curr Pharm Biotechnol. 2017;18(3):194-203. doi: 10.2174/1389201018666170224105600.
6
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.药物可作为人细胞色素P450 3A4的底物、抑制剂和诱导剂。
Curr Drug Metab. 2008 May;9(4):310-22. doi: 10.2174/138920008784220664.
Zotero 插件